|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
EP2360164A3
(de)
*
|
2004-03-16 |
2012-01-04 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
NZ566787A
(en)
*
|
2005-09-08 |
2010-02-26 |
Boehringer Ingelheim Int |
Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
EA030606B1
(ru)
|
2006-05-04 |
2018-08-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способы приготовления лекарственного средства, содержащего полиморфы
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
US8039441B2
(en)
*
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
|
WO2008034859A1
(en)
*
|
2006-09-21 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
EP2086991A1
(en)
*
|
2006-10-27 |
2009-08-12 |
Boehringer Ingelheim International GmbH |
CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
|
|
US7879807B2
(en)
|
2007-02-21 |
2011-02-01 |
Boehringer Ingelheim International Gmbh |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
WO2009035969A1
(en)
|
2007-09-10 |
2009-03-19 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of sglt
|
|
PE20091211A1
(es)
|
2007-11-30 |
2009-09-14 |
Boehringer Ingelheim Int |
Derivados de pirazolopirimidina como moduladores de pde9a
|
|
ES2541141T3
(es)
*
|
2008-01-31 |
2015-07-16 |
Astellas Pharma Inc. |
Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
AR072511A1
(es)
|
2008-07-15 |
2010-09-01 |
Theracos Inc |
Derivados deuterados de bencilbenceno y metodos de uso. composicion farmaceutica.
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
CN102149717B
(zh)
|
2008-08-28 |
2014-05-14 |
辉瑞大药厂 |
二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
|
|
AP2011005672A0
(en)
|
2008-09-08 |
2011-04-30 |
Boehringer Ingelheim Int |
Pyrazolopyrimidines and their use for the treatment of CNS disorders.
|
|
MX2011002558A
(es)
|
2008-09-10 |
2011-04-26 |
Boehringer Ingelheim Int |
Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
US9056850B2
(en)
*
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
PE20120106A1
(es)
|
2008-12-09 |
2012-02-20 |
Gilead Sciences Inc |
Moduladores de receptores tipo toll
|
|
CN102256976A
(zh)
|
2008-12-23 |
2011-11-23 |
贝林格尔.英格海姆国际有限公司 |
有机化合物的盐形式
|
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
|
CN104138370A
(zh)
*
|
2009-02-13 |
2014-11-12 |
贝林格尔.英格海姆国际有限公司 |
用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
|
|
KR101921934B1
(ko)
|
2009-02-13 |
2018-11-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도
|
|
UY32427A
(es)
*
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
AU2016213789B2
(en)
*
|
2009-02-13 |
2018-01-18 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
LT2395983T
(lt)
*
|
2009-02-13 |
2020-07-10 |
Boehringer Ingelheim International Gmbh |
Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
|
|
PE20120505A1
(es)
|
2009-03-31 |
2012-05-09 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
|
|
US20110009347A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
EP2451797B1
(en)
|
2009-07-10 |
2013-04-03 |
Janssen Pharmaceutica, N.V. |
CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
|
|
JP5767643B2
(ja)
|
2009-09-21 |
2015-08-19 |
ギリード・サイエンシズ・インコーポレーテッド |
１’−置換カルバヌクレオシド類似体の調製のためのプロセスおよび中間体
|
|
PH12012500633B1
(en)
|
2009-09-30 |
2017-12-13 |
Boehringer Ingelheim Int |
Method for the preparation of a crystalline form of 1-chloro -4- (beta -d- glucopyranos -1-yl) -2- (4-((s)- tetrahydrofuran -3- yloxy) benzyl) benzene
|
|
WO2011039108A2
(en)
|
2009-09-30 |
2011-04-07 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
|
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
|
WO2011047113A1
(en)
|
2009-10-14 |
2011-04-21 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
WO2011051864A1
(en)
|
2009-11-02 |
2011-05-05 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
|
EA034869B1
(ru)
|
2009-11-27 |
2020-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
JP2013523681A
(ja)
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
|
|
KR101819609B1
(ko)
|
2010-05-05 |
2018-01-17 |
베링거 인겔하임 인터내셔날 게엠베하 |
체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
|
|
MY187718A
(en)
|
2010-05-11 |
2021-10-14 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations
|
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
KR20230051307A
(ko)
|
2010-06-24 |
2023-04-17 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
PE20130400A1
(es)
|
2010-07-22 |
2013-04-10 |
Gilead Sciences Inc |
Metodos y compuestos para tratar infecciones virales por paramyxoviridae
|
|
HUE033378T2
(en)
|
2010-08-12 |
2017-11-28 |
Boehringer Ingelheim Int |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
EA201300522A1
(ru)
|
2010-11-02 |
2013-11-29 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Фармацевтические комбинации для лечения метаболических нарушений
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
|
CN103596944B
(zh)
|
2011-04-13 |
2017-02-22 |
詹森药业有限公司 |
可用作sglt2的抑制剂的化合物的制备方法
|
|
US9035044B2
(en)
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
|
AU2012264736A1
(en)
|
2011-06-03 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
MX366629B
(es)
|
2011-07-15 |
2019-07-17 |
Boehringer Ingelheim Int |
Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
BR112014027884A2
(pt)
|
2012-05-09 |
2017-06-27 |
Boehringer Ingelheim Int |
combinações farmacêuticas para tratamento de distúrbios metabólicos
|
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
|
JP6218811B2
(ja)
|
2012-05-14 |
2017-10-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
WO2014161836A1
(en)
|
2013-04-04 |
2014-10-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HK1213818A1
(zh)
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
依帕列净的治疗用途
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
|
EA033286B1
(ru)
|
2013-04-18 |
2019-09-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способ лечения или отсрочки развития хронической болезни почек
|
|
ES2605886T3
(es)
|
2013-09-27 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Derivados de glucopiranosilo y sus usos en medicina
|
|
CN105828815B
(zh)
|
2013-12-17 |
2020-03-27 |
勃林格殷格翰动物保健有限公司 |
猫科动物中代谢紊乱的治疗
|
|
ES2951127T3
(es)
*
|
2014-01-23 |
2023-10-18 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales caninos
|
|
WO2015128453A1
(en)
|
2014-02-28 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Medical use of a dpp-4 inhibitor
|
|
AU2015239655B2
(en)
|
2014-04-01 |
2019-10-24 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
|
CN103965020B
(zh)
*
|
2014-05-06 |
2015-09-09 |
启东东岳药业有限公司 |
制备5-碘-2-溴苄醇的方法
|
|
KR20190104438A
(ko)
|
2014-07-11 |
2019-09-09 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv의 치료를 위한 톨-유사 수용체의 조정제
|
|
CN106715431A
(zh)
|
2014-09-16 |
2017-05-24 |
吉利德科学公司 |
Toll样受体调节剂的固体形式
|
|
NZ728804A
(en)
|
2014-09-25 |
2022-10-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
|
|
TWI698444B
(zh)
*
|
2014-10-29 |
2020-07-11 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
|
AU2016229982B2
(en)
|
2015-03-09 |
2020-06-18 |
Intekrin Therapeutics, Inc. |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
|
RS66325B1
(sr)
|
2015-08-27 |
2025-01-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Tečne farmaceutske kompozicije koje obuhvataju inhibitore sglt 2
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
PT3349758T
(pt)
|
2015-09-16 |
2022-07-13 |
Gilead Sciences Inc |
Métodos para o tratamento de infeções pelo vírus arenaviridae
|
|
WO2017064193A1
(en)
|
2015-10-15 |
2017-04-20 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
|
US10155000B2
(en)
|
2016-06-10 |
2018-12-18 |
Boehringer Ingelheim International Gmbh |
Medical use of pharmaceutical combination or composition
|
|
JP7625363B2
(ja)
|
2016-11-10 |
2025-02-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
医薬組成物、治療方法及びその使用
|
|
CN110869028B
(zh)
|
2017-03-14 |
2023-01-20 |
吉利德科学公司 |
治疗猫冠状病毒感染的方法
|
|
JP2020515639A
(ja)
|
2017-04-03 |
2020-05-28 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
|
|
KR20190141747A
(ko)
|
2017-05-01 |
2019-12-24 |
길리애드 사이언시즈, 인코포레이티드 |
(S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
|
|
US10675296B2
(en)
|
2017-07-11 |
2020-06-09 |
Gilead Sciences, Inc. |
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
AU2020394498A1
(en)
|
2019-11-28 |
2022-06-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors in the drying-off of non-human mammals
|
|
CN118766947A
(zh)
|
2020-01-27 |
2024-10-15 |
吉利德科学公司 |
用于治疗SARS CoV-2感染的方法
|
|
AU2021222297A1
(en)
|
2020-02-17 |
2022-08-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
|
BR112022017189A2
(pt)
|
2020-03-06 |
2022-10-18 |
Vertex Pharma |
Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1
|
|
CA3169340A1
(en)
|
2020-03-12 |
2021-09-16 |
Pavel R. Badalov |
Methods of preparing 1'-cyano nucleosides
|
|
JP7482250B2
(ja)
|
2020-04-06 |
2024-05-13 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノ置換カルバヌクレオシド類似体の吸入製剤
|
|
PL4157272T3
(pl)
|
2020-05-29 |
2025-10-20 |
Gilead Sciences, Inc. |
Remdesiwir do leczenia zakażeń wirusowych
|
|
JP2023531524A
(ja)
|
2020-06-24 |
2023-07-24 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノヌクレオシド類似体及びその使用
|
|
LT4204421T
(lt)
|
2020-08-27 |
2024-06-25 |
Gilead Sciences, Inc. |
Virusinių infekcijų gydymui skirti junginiai ir būdai
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
MX2024001184A
(es)
|
2021-07-28 |
2024-02-27 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
|
|
EP4376819A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
|
US20240307426A1
(en)
|
2021-07-28 |
2024-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
|
US20250170128A1
(en)
|
2021-12-30 |
2025-05-29 |
NEWAMSTERDAM PHARMA B.V. (Dutch Chamber of Commerce No. 5597 1946) |
Obicetrapib and SGLT2 Inhibitor Combination
|
|
US20230295172A1
(en)
|
2022-03-02 |
2023-09-21 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
US20230381101A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
|
WO2024184293A1
(en)
|
2023-03-06 |
2024-09-12 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
|
TW202446389A
(zh)
|
2023-04-24 |
2024-12-01 |
荷蘭商新阿姆斯特丹製藥公司 |
非晶形奧比特拉(obicetrapib)與sglt2抑制劑之組合
|
|
US20240390317A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|
|
WO2024240633A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|